BioArctic (LSE:0RV2) - Stock Price, News & Analysis

0RV2 Stock Overview

BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden.

0RV2 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	6/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 79.2% below our estimate of its fair value

Earnings are forecast to grow 48.19% per year

Became profitable this year

Analysts in good agreement that stock price will rise by 89%

Risk Analysis

Volatile share price over the past 3 months

BioArctic AB (publ) Competitors

Genus

LSE:GNS

UK£1.2b

NIOX Group

AIM:NIOX

UK£273.9m

Bioventix

AIM:BVXP

UK£240.1m

HUTCHMED (China)

AIM:HCM

UK£2.3b

Price History & Performance

Summary of all time highs, changes and price drops for BioArctic
Historical stock prices
Current Share Price	kr193.81
52 Week High	kr391.00
52 Week Low	kr189.90
Beta	-0.17
1 Month Change	-13.46%
3 Month Change	-16.31%
1 Year Change	-17.47%
3 Year Change	105.53%
5 Year Change	142.42%
Change since IPO	617.82%

Recent updates

Shareholder Returns

	0RV2	GB Biotechs	GB Market
7D	-2.5%	-2.4%	-1.4%
1Y	-17.5%	-29.6%	-2.4%

Return vs Industry: 0RV2 exceeded the UK Biotechs industry which returned -29.6% over the past year.

Return vs Market: 0RV2 underperformed the UK Market which returned -2.4% over the past year.

Price Volatility

Is 0RV2's price volatile compared to industry and market?
0RV2 volatility
0RV2 Average Weekly Movement	7.6%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.5%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0RV2's share price has been volatile over the past 3 months.

Volatility Over Time: 0RV2's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2000	88	Gunilla Osswald	www.bioarctic.se

BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. It also develops ABBV-0805, for treating Parkinson’s disease.

BioArctic AB (publ) Fundamentals Summary

How do BioArctic's earnings and revenue compare to its market cap?
0RV2 fundamental statistics
Market cap	kr17.12b
Earnings (TTM)	kr229.25m
Revenue (TTM)	kr620.08m

74.7x

P/E Ratio

27.6x

P/S Ratio

Is 0RV2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RV2 income statement (TTM)
Revenue	kr620.08m
Cost of Revenue	kr89.63m
Gross Profit	kr530.45m
Other Expenses	kr301.20m
Earnings	kr229.25m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 17, 2024

Earnings per share (EPS)	2.60
Gross Margin	85.55%
Net Profit Margin	36.97%
Debt/Equity Ratio	0%

How did 0RV2 perform over the long term?

See historical performance and comparison

0RV2 Stock Overview

Rewards

Risk Analysis

BioArctic AB (publ) Competitors

LSE:GNS

UK£1.2b

AIM:NIOX

UK£273.9m

AIM:BVXP

UK£240.1m

AIM:HCM

UK£2.3b

Price History & Performance

Recent News & Updates

New minor risk - Share price stability

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings released: EPS: kr1.42 (vs kr1.55 in 3Q 2022)

Recent updates

New minor risk - Share price stability

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings released: EPS: kr1.42 (vs kr1.55 in 3Q 2022)

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research recently sold kr2.8m worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022)

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Independent Director recently sold kr3.3m worth of stock

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released: EPS: kr1.55 (vs kr0.43 loss in 3Q 2021)

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic)

Second quarter 2022 earnings released: kr0.52 loss per share (vs kr0.39 loss in 2Q 2021)

Insider recently bought kr100k worth of stock

First quarter 2022 earnings released

Insufficient new directors

Full year 2021 earnings released: kr1.36 loss per share (vs kr0.78 loss in FY 2020)

Independent Deputy Chairman recently bought kr824k worth of stock

Bioarctic AB Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioArctic AB (publ) to Report Fiscal Year 2021 Final Results on Mar 31, 2022

DIAN-TU Enrolls First Subject for the Tau Nexgen Study with Lecanemab as Back-Ground Anti-Amyloid Treatment

Bioarctic AB (Publ) Announces Lecanemab Granted Fast Track Designation by the FDA

Third quarter 2021 earnings released

BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

Chief Medical Officer recently bought kr103k worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease

Independent Director has left the company

First quarter 2021 earnings released: kr0.33 loss per share (vs kr0.04 profit in 1Q 2020)

Bioarctic and Eisai Present Latest Data Regarding Lecanemab at AD/PD 2021

Bioarctic AB (Publ) and Eisai to Present Data Relating to Its Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody Lecanemab (BAN2401)

BioArctic AB (publ) Announces Board Changes

Full year 2020 earnings released: kr0.78 loss per share (vs kr1.01 profit in FY 2019)

Revenue beats expectations

BioArctic AB (publ) to Report Fiscal Year 2020 Final Results on Mar 31, 2021

BioArctic AB Increases the Number of Participants in Clarity AD Study

New 90-day high: kr122